1. accedaCRIS
  2. Publicaciones
  3. Artículos
Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/53000
DC FieldValueLanguage
dc.contributor.authorRodriguez-Perez, Jose C.
dc.contributor.authorGarcia-Bello, Miguel A.
dc.contributor.authorAnabitarte-Prieto, Aranzazu
dc.contributor.authorCompanioni, Osmel
dc.contributor.authorNovoa-Mogollon, Francisco J.
dc.contributor.authorSuarez-Ortega, Saturnino
dc.contributor.authorPlaza-Toledano, Celia
dc.contributor.authorRodriguez-Esparragon, Francisco
dc.contributor.otherRodriguez-Perez, J.C.
dc.contributor.otherRodriguez-Esparragon, Francisco
dc.contributor.otherGarcia-Bello, Miguel-Angel
dc.date.accessioned2019-02-04T14:40:36Z-
dc.date.available2019-02-04T14:40:36Z-
dc.date.issued2011
dc.identifier.issn1064-1963
dc.identifier.urihttp://hdl.handle.net/10553/53000-
dc.description.abstractWe evaluated the anti-hypertensive and anti-albuminuric effect of the angiotensin receptor blocker telmisartan alone and in combination with torasemide and amlodipine. Patients were hypertensive, both diabetics and non-diabetics with persistent microalbuminuria. Our primary endpoint was a change in microalbuminuria levels, while the secondary endpoints were changes in systolic blood pressure (SBP), diastolic blood pressure (DBP), serum creatinine levels, and glomerular filtration rate. After the 16-week treatment period, the patients significantly reduced microalbuminuria levels (76.4 +/- 52.4 mu g/min; p < 0.001), SBP (16.4 +/- 8.7 mmHg; p < 0.001) and DBP (17.7 +/- 5.9 mmHg; p < 0.001). Both diabetics and non-diabetics showed an identical pattern of significance with respect to the whole population. Systolic blood pressure, DBP, and microalbuminuria were significantly reduced as a consequence of therapy, both in diabetics and non-diabetics.
dc.publisher1064-1963
dc.relation.ispartofClinical and Experimental Hypertension
dc.sourceClinical And Experimental Hypertension[ISSN 1064-1963],v. 33 (8), p. 506-510
dc.subject.otherRandomized Controlled-Trial
dc.subject.otherBlood-Pressure
dc.subject.otherOvert Nephropathy
dc.subject.otherHigh-Risk
dc.subject.otherPrevention
dc.subject.otherGuidelines
dc.subject.otherValsartan
dc.subject.otherLosartan
dc.subject.otherEvents
dc.titleAnti-Albuminuric Effects of the Angiotensin AT1 Receptor Blocker Telmisartan in Hypertensive Patients
dc.typeinfo:eu-repo/semantics/Article
dc.typeArticle
dc.identifier.doi10.3109/10641963.2011.561900
dc.identifier.scopus82455198894
dc.identifier.isi000297470200002
dcterms.isPartOfClinical And Experimental Hypertension
dcterms.sourceClinical And Experimental Hypertension[ISSN 1064-1963],v. 33 (8), p. 506-510
dc.contributor.authorscopusid54412956400
dc.contributor.authorscopusid54412123900
dc.contributor.authorscopusid6506385286
dc.contributor.authorscopusid14061836500
dc.contributor.authorscopusid12786120600
dc.contributor.authorscopusid7003480889
dc.contributor.authorscopusid18034771800
dc.contributor.authorscopusid6603262370
dc.description.lastpage510
dc.identifier.issue8
dc.description.firstpage506
dc.relation.volume33
dc.type2Artículo
dc.identifier.wosWOS:000297470200002
dc.contributor.daisngid245684
dc.contributor.daisngid1700450
dc.contributor.daisngid10185782
dc.contributor.daisngid2952487
dc.contributor.daisngid4992898
dc.contributor.daisngid6018799
dc.contributor.daisngid9742321
dc.contributor.daisngid1305938
dc.identifier.investigatorRIDC-1247-2010
dc.identifier.investigatorRIDD-2810-2013
dc.identifier.investigatorRIDNo ID
dc.contributor.wosstandardWOS:Rodriguez-Perez, JC
dc.contributor.wosstandardWOS:Garcia-Bello, MA
dc.contributor.wosstandardWOS:Anabitarte-Prieto, A
dc.contributor.wosstandardWOS:Companioni, O
dc.contributor.wosstandardWOS:Novoa-Mogollon, FJ
dc.contributor.wosstandardWOS:Suarez-Ortega, S
dc.contributor.wosstandardWOS:Plaza-Toledano, C
dc.contributor.wosstandardWOS:Rodriguez-Esparragon, F
dc.date.coverdateDiciembre 2011
dc.identifier.ulpgcSíes
dc.description.sjr0,403
dc.description.jcr1,074
dc.description.sjrqQ2
dc.description.jcrqQ4
dc.description.scieSCIE
item.fulltextSin texto completo-
item.grantfulltextnone-
crisitem.author.deptGIR IUIBS: Patología y Tecnología médica-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptGIR IUCES: Estrategia y Negocios Internacionales-
crisitem.author.deptIU de Cibernética, Empresa y Sociedad (IUCES)-
crisitem.author.deptDepartamento de Economía y Dirección de Empresas-
crisitem.author.deptGIR IUSA-ONEHEALTH 5: Reproducción Animal, Oncología y Anestesiología Comparadas-
crisitem.author.deptIU de Sanidad Animal y Seguridad Alimentaria-
crisitem.author.orcid0000-0003-0023-1063-
crisitem.author.orcid0000-0002-2540-5042-
crisitem.author.orcid0000-0003-1663-3673-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.parentorgIU de Cibernética, Empresa y Sociedad (IUCES)-
crisitem.author.parentorgIU de Sanidad Animal y Seguridad Alimentaria-
crisitem.author.fullNameRodríguez Pérez,José Carlos-
crisitem.author.fullNameSuárez Ortega, Sonia María-
crisitem.author.fullNameRodríguez Esparragón,Francisco Javier-
Appears in Collections:Artículos
Show simple item record

SCOPUSTM   
Citations

2
checked on Sep 22, 2024

WEB OF SCIENCETM
Citations

2
checked on Sep 22, 2024

Page view(s)

58
checked on Mar 2, 2024

Google ScholarTM

Check

Altmetric


Share


Export metadata


Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.